0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-17A

IL-17A

IL-17A Molecule Information

Name:Interleukin 17A
Target Synonym:Interleukin-17A;CTLA8 ;IL-17A;CTLA-8;IL17;IL-17;Cytotoxic T-lymphocyte-associated antigen 8;IL17A
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

IL-17A Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
ILA-H82Q1 Human Biotinylated Human IL-17A / CTLA-8 Protein, His,Avitag™
ILA-H82Q1-structure
ILA-H82Q1-sds
ILA-H82Q1-elisa_1
CT8-M5240 Mouse Mouse IL-17A / CTLA-8 Protein, His Tag
CT8-M5240-structure
CT8-M5240-sds
CT8-M5240-elisa_1
ILA-H5118 Human Human IL-17A / CTLA-8 Protein, Tag Free 
ILA-H5118-structure
ILA-H5118-sds
ILA-H5118-elisa_1

IL-17A Molecule Synonym Name

IL-17A,Interleukin-17A,CTLA-8,IL-17

IL-17A Molecule Background

Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

IL-17A References

IL-17A Related Molecule

IL-17A Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Virulizin Approved Aptose, Symbion Health, Zor Pharmaceuticals Gastric cancer, Colorectal cancer, Renal carcinoma, Cervical carcinoma, Kaposi's sarcoma, Pancreatic cancer, Melanoma Details
Ixekizumab LY-2439821, LY2439821 Approved Lilly TALTZ fda Plaque psoriasis ELI LILLY AND CO 2016-03-22 Psoriatic erythroderma, Plaque psoriasis, Pustular psoriasis, Psoriatic arthritis, Psoriasis vulgaris Details
Secukinumab AIN-457; KB-03303A; NVP-AIN-457 Approved Novartis, Maruho Pharmaceutical Secukinumab 日本 Psoriasis vulgaris, Psoriatic arthritis 诺华,Maruho Pharmaceutical 2014-12-26 00:00:00.0 Plaque psoriasis, Ankylosing Spondylitis (AS), Pustular psoriasis, Psoriasis, Psoriatic arthritis, Psoriasis vulgaris Details

IL-17A Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tibulizumab (Eli Lilly) Phase Ⅰ Lilly Sjoegren's syndrome Details
ALX-0761 ALX-0761; M-1095; MSB-0010841 Phase Ⅱ Ablynx, Merck Serono Psoriasis Details
JNJ-63823539 JNJ-63823539 Phase Ⅰ Janssen Rheumatoid arthritis (RA) Details
RO-7040547 BIT-7201A; RG-7990; RO-7040547 Phase Ⅰ Genentech Allergic asthma Details
Vidofludimus 4SC-101; SC-12267,4SC101,SC12267 Phase Ⅱ 4SC AG Ulcerative colitis, Crohn's disease Details
Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) JS005 Phase Ⅰ Shanghai Junshi Biosciences Plaque psoriasis, Psoriasis, Rheumatoid arthritis (RA) Details
COVA-322 COVA-322 Phase Ⅱ Covagen Plaque psoriasis Details
UCB-0159 UCB-0159 Phase Ⅰ UCB Autoimmune diseases Details
Vunakizumab SHR-1314 Phase Ⅱ Jiangsu Hengrui Medicine Spondyloarthritis, Plaque psoriasis Details
ABY-035 ABY-035; AFB-035 Phase Ⅰ Affibody Psoriasis Details
Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai CP Guojian) Phase Ⅰ Shanghai CP Guojian Plaque psoriasis Details
SCH-900117 SCH-900117; SCH900117 Phase Ⅰ Merck Sharp & Dohme Rheumatoid arthritis (RA) Details
CJM-112 CJM-112 Phase Ⅱ Novartis Plaque psoriasis, Hidradenitis suppurativa, Multiple sclerosis (MS) Details

This web search service is supported by Google Inc.

totop